Alpha 2.0
Login Register
» Authors » Ayal Hirsch

Ayal Hirsch

Explore the profile of Ayal Hirsch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 235
Followers 0
Related Specialties
Gastroenterology
General Medicine
Pharmacology
Top 10 Co-Authors
Nitsan Maharshak
Yulia Ron
Nathaniel Aviv Cohen
David T Rubin
Naomi Fliss Isakov
Uri Kopylov
Iris Dotan
Henit Yanai
Eran Zittan
Rami Eliakim
Published In
Dig Dis Sci
J Crohns Colitis
Clin Gastroenterol Hepatol
Nutrients
J Clin Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Ultra-Processed Foods Consumption Is Positively Associated with the Clinical Activity of Inflammatory Bowel Diseases: A Cross-Sectional Single-Center Study
Sarbagili-Shabat C, Zelber-Sagi S, Fliss Isakov N, Hirsch A, Ron Y, Grinshpan L, et al.
Inflamm Intest Dis . 2024 Oct; 9(1):241-251. PMID: 39474331
Introduction: Western diet pattern and its food components have been suggested to impact inflammatory bowel diseases (IBDs) clinical course. However, the importance of food processing level is uncertain. We aimed...
2.
Pro-motility Preparation Protocol May Reduce the Rates of Failed Patency Capsule Among Patients with Crohn's Disease in Clinical Remission
Ukashi O, Dotan A, Borkovsky T, Talan Asher A, Thurm T, Hirsch A, et al.
Dig Dis Sci . 2024 Oct; 69(11):4178-4186. PMID: 39384710
Background: Patency capsule (PC) ingestion is commonly used to minimize capsule retention in high-risk patients with Crohn's disease (CD). However, false-positive rates remain high, precluding the use of video capsule...
3.
Faecal Transplantation for Ulcerative Colitis From Diet Conditioned Donors Followed by Dietary Intervention Results in Favourable Gut Microbial Profile Compared to Faecal Transplantation Alone
Leibovitzh H, Sarbagili Shabat C, Hirsch A, Zittan E, Mentella M, Petito V, et al.
J Crohns Colitis . 2024 May; 18(10):1606-1614. PMID: 38720628
Background And Aims: Several faecal microbial transplantation [FMT] approaches for ulcerative colitis [UC] have been investigated with conflicting results. We have recently published the clinical outcomes from the CRAFT UC...
4.
Medical Cannabis Increases Appetite but Not Body Weight in Patients with Inflammatory Bowel Diseases
Fliss Isakov N, Seidenberg C, Meiri D, Yackobovitch-Gavan M, Maharshak N, Hirsch A
Nutrients . 2024 Jan; 16(1). PMID: 38201908
We aimed to elucidate the effect of Medical Cannabis (MC) on appetite and nutritional status among patients with inflammatory bowel disease (IBD). A case series of patients with IBD were...
5.
Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn's Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study
Hirsch A, Scapa E, Fliss-Isakov N, Tulchinsky H, Itzkowitz E, Kariv Y, et al.
J Clin Med . 2023 Dec; 12(24). PMID: 38137669
Postoperative recurrence (POR) is the rule in patients with Crohn's disease (CD), mitigated with prophylactic therapy. The evidence for therapeutic choice and timing of intervention is lacking. We aimed to...
6.
Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
Harnik S, Abitbol C, Haj Natour O, Yavzori M, Fudim E, Picard O, et al.
J Crohns Colitis . 2023 Sep; 18(3):341-348. PMID: 37691574
Background And Aims: Home self-injection of the human anti-tumour necrosis alpha [anti-TNFα] monoclonal adalimumab complicates prospective serial-sampling studies. Although a recent study examined adalimumab levels and immunogenicity in Crohn's disease...
7.
Crohn's Disease Exclusion Diet for the Treatment of Crohn's Disease: Real-World Experience from a Tertiary Center
Fliss-Isakov N, Cohen N, Bromberg A, Elbert G, Anbar R, Ron Y, et al.
J Clin Med . 2023 Aug; 12(16). PMID: 37629470
The Crohn's Disease (CD) exclusion diet (CDED) has been shown to induce remission in pediatric and adult patients with CD. In this retrospective cohort study, we describe our real-world experience...
8.
Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial
Ben-Horin S, Salomon N, Karampekos G, Viazis N, Lahat A, Ungar B, et al.
Clin Gastroenterol Hepatol . 2023 Jun; 22(2):347-356.e6. PMID: 37302449
Background & Aims: We evaluated the efficacy of herbal combination of curcumin-QingDai (CurQD) in active ulcerative colitis (UC). Methods: Part I was an open-label trial of CurQD in patients with...
9.
Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study
Yanai H, Salomon N, Lahat A, Ungar B, Eliakim R, Kriger-Sharabi O, et al.
Aliment Pharmacol Ther . 2023 May; 58(2):175-181. PMID: 37157131
Background: Curcumin and QingDai (QD, Indigo) have been shown to be effective for treating active ulcerative colitis (UC). Aim: To evaluate the real-world experience with the Curcumin-QingDai (CurQD) herbal combination...
10.
The Effect of the Crohn's Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study
Fliss Isakov N, Kornblum J, Zemel M, Cohen N, Hirsch A, Maharshak N
Clin Gastroenterol Hepatol . 2022 Apr; 21(6):1654-1656.e3. PMID: 35447313
Restorative proctocolectomy with ileal pouch-anal anastomosis is the surgical treatment of choice for patients with ulcerative colitis. Unfortunately, pouch inflammation (ie, pouchitis) is reported in up to 72% of pouch...